Premium
P3‐309: Pyroglutamate modified Abeta accumulates around synapses and micro‐plaques early in the development of Alzheimer's disease
Author(s) -
Mandler Markus,
Santic Radmila,
Kopinits Edith,
Adame Anthony,
Rockenstein Edward,
Mattner Frank,
Masliah Eliezer
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.1810
Subject(s) - neuropil , immunostaining , monoclonal antibody , pathology , antibody , neurotoxicity , chemistry , biology , neuroscience , immunohistochemistry , microbiology and biotechnology , immunology , medicine , central nervous system , toxicity , organic chemistry
Immunocytochemical analysis in the brains of patients with MCI and Braak stage I-III showed that D129 recognized granular deposits in the neuropil as well as micro-plaques distributed around axons and dendrites. D129 punctuate immunostaining co-localized with PSD95. Such deposits were not identified with the 3A5 antibody. In later stage AD cases, at Braak stages IV-VI, the antibody D129 recognized diffuse and dense amyloid deposits both with a granular or fibrillar appearance. Similarly, in two APP tg mice (mThy1-mutant APP751; line 41 and Tg2576) at early stages D129 recognized granular deposits in the neuropil that co-localized with PSD95. At later stages (pE)-Abeta immunostaining was associated with diffuse and dense plaques. In brains of APP tg mice and AD cases, intracellular staining was only detectable using the 3A5 antibody, but not with the D129 antibody.